Cagri + Semaglutide

Cagrilintide + Semaglutide is a research combination pairing two compounds that act through complementary metabolic signaling pathways. Cagrilintide is a long-acting amylin analog studied for its activity at amylin-associated receptors, while semaglutide is a GLP-1 receptor agonist investigated for its effects on GLP-1 receptor signaling.

The combination is studied in laboratory and clinical research involving metabolic regulation, glucose and lipid metabolism, energy homeostasis, appetite-related signaling, and interactions between amylin and GLP-1 pathways.

Research Classification: Amylin analog + GLP-1 receptor agonist combination Form: Research peptide combination Intended Use: Laboratory research

Research Use Only. Not for human or veterinary use. This product is intended solely for qualified laboratory research and analytical applications. It is not intended to diagnose, treat, cure, or prevent any disease.